Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

EMBRACE CHANGE ACQUISITION CORP.

(Exact Name of Registrant as Specified in Charter)

Cayman Islands

001-41397

N/A00-0000000

(State or Other Jurisdiction of

Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

5186 Carroll Canyon Rd

San Diego, CA 92121

(Address of Principal Executive Offices) (Zip Code)

(858) 688-4965

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one ordinary share, one right and one warrant	EMCGU	The Nasdaq Stock Market LLC
Ordinary Shares	EMCG	The Nasdaq Stock Market LLC
Rights	EMCGR	The Nasdaq Stock Market LLC
Warrants	EMCGW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of July 30, 2024, there were 7,423,175 ordinary shares, $0.0001 par value issued and outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION		1
Item 1. Financial Statements		1
Balance Sheets of March 31, 2024 and December 31, 2023 (Unaudited)		1
Statements of Operations for the three months ended March 31, 2024 (Unaudited) and for the three months ended March 31, 2023 (Unaudited)		2
Statements of Changes in Stockholders’ Deficit for the three months ended March 31, 2024 (Unaudited) and for the three months ended March 31, 2023 (Unaudited)		3
Statements of Cash Flows for the three months ended March 31, 2024 (Unaudited) and for the three months ended March 31, 2023 (Unaudited)		4
Notes to Financial Statements (Unaudited)		5
Item 2. Management’s Discussion and Analysis of Financial Statements		18
Item 3. Quantitative and Qualitative Disclosure about Market Risks		23
Item 4. Controls and Procedures		23

PART II. OTHER INFORMATION		24
Item 1. Legal Proceedings		24
Item 1A. Risk Factors		24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		24
Item 3. Defaults Upon Senior Securities		25
Item 4. Mine Safety Disclosures		25
Item 5. Other Information		25
Item 6. Exhibits		26

Signatures		27

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

EMBRACE CHANGE ACQUISITION CORP.

BALANCE SHEETS

(Unaudited)


	March 31,			December 31,
	2024			2023
ASSETS
Cash	$	5,308		$	5,308
Total Current Assets		5,308			5,308
Marketable securities held in trust account		57,266,630			56,231,052
Total assets	$	57,271,938		$	56,236,360

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accrued expenses	$	1,049,333		$	1,077,258
Due to related party		62,260			54,535
Convertible promissory note – related party		770,112			400,112
Total current liabilities		1,881,705			1,531,905
Deferred underwriter fee payable		2,966,000			2,587,499
Total liabilities		4,847,705			4,119,404

Commitments and Contingencies (Note 6)
Ordinary shares subject to possible redemption, 5,127,282 and 5,127,282 shares issued and outstanding at redemption value of $11.17 per share and $10.97 per share as of March 31, 2024 and December 31, 2023, respectively		57,266,630			56,231,052

Stockholders’ Deficit
Ordinary Shares, par value $0.0001; 500,000,000 shares authorized; 2,295,893 (excluding 5,127,282 and 5,127,282 shares subject to redemption, respectively) issued and outstanding as of March 31, 2024 and December 31, 2023, respectively		230			230
Additional paid-in capital		-			-
Accumulated deficit		(4,842,627	)		(4,114,326	)
Total Stockholders’ Deficit		(4,842,397	)		(4,114,096	)

Total Liabilities and Stockholders’ Deficit	$	57,271,938		$	56,236,360

The accompanying notes are an integral part of these unaudited financial statements.

EMBRACE CHANGE ACQUISITION CORP.

STATEMENTS OF OPERATIONS

(Unaudited)


	For the			For the
	three months ended			three months ended
	March 31, 2024			March 31, 2023
Formation and operating costs	$	49,800		$	(128,263	)
Loss from operations		(49,800	)		(128,263	)
Other income (loss):
Investment income earned on investments held in Trust Account		735,578			822,317
Loss on modification of deferred underwriting commission		(378,501	)		-
Total other income (loss)		357,077			822,317
Net income	$	307,277		$	694,054
Weighted average shares outstanding, basic and diluted		7,423,175			9,688,748
Basic and diluted net income per ordinary share	$	0.04		$	0.07

The accompanying notes are an integral part of these unaudited financial statements.

EMBRACE CHANGE ACQUISITION CORP.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2024

(Unaudited)


					Additional					Total
	Ordinary shares				Paid in		Accumulated			Stockholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance – December 31, 2023		2,295,893	$	230	$	-	$	(4,114,326	)	$	(4,114,096	)
Amount deposited into trust account subject to redemption		-		-		-		(300,000	)		(300,000	)
Re-measurement of ordinary shares subject to redemption		-		-		-		(735,578	)		(735,578	)
Net income		-		-		-		307,277			307,277
Balance – March 31, 2024		2,295,893	$	230	$	-	$	(4,842,627	)	$	(4,842,397	)

EMBRACE CHANGE ACQUISITION CORP.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Unaudited)

					Additional					Total
	Ordinary shares				Paid in		Accumulated			Stockholders’
	Shares⁽¹⁾		Amount		Capital		Deficit			Deficit
Balance – December 31, 2022		2,295,893	$	230	$	-	$	(2,341,247	)	$	(2,341,017	)
Re-measurement of ordinary shares subject to redemption		-		-		-		(822,317	)		(822,317	)
Net income		-		-		-		694,054			694,054
Balance – March 31, 2023		2,295,893	$	230	$	-	$	(2,469,510	)	$	(2,469,280	)

The accompanying notes are an integral part of these unaudited financial statements.

EMBRACE CHANGE ACQUISITION CORP.

STATEMENTS OF CASH FLOWS

(Unaudited)


	For the three months ended March 31, 2024			For the three months ended March 31, 2023
Cash flow from operating activities:
Net income	$	307,277		$	694,054
Adjustments to reconcile net income to net cash used in operating activities:
Investment income earned on investments held in Trust Account		(735,578	)		(822,317	)
Loss on modification of deferred underwriting commission		378,501			-
Changes in operating assets and liabilities:
Other receivables		-			521
Accounts payable and accrued expenses		(27,925	)		123,213
Net cash used in operating activities		(77,725	)		(4,529	)

Cash flows from investing activities:
Investment of cash in Trust Account		(300,000	)		-
Net cash used in investing activities		(300,000	)		-

Cash flow from financing activities:
Proceeds from convertible promissory note - related party		370,000			-
Proceeds from related party for working capital purpose		7,725			-
Net cash provided by financing activities		377,725			-

Net change in cash		-			(4,529	)
Cash at the beginning of the period		5,308			403,012
Cash at the end of the period	$	5,308		$	398,483

Supplemental disclosure of non-cash financing activities:
Deferred underwriting fee payable	$	378,501		$	-
Re-measurement of ordinary shares subject to redemption⁽¹⁾	$	735,578		$	822,317
Extension funds attributable to ordinary shares to redemption	$	300,000		$	-

(1)

The value of ordinary share subject to redemption was re-measured with investment income earned on investments held in Trust Account.

The accompanying notes are an integral part of these unaudited financial statements.

EMBRACE CHANGE ACQUISITION CORP.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

Embrace Change Acquisition Corp. (the “Company”) is a blank check company incorporated in the Cayman Islands on March 3, 2021. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities (“Business Combination”). The Company may pursue a business combination target in any business or industry.

As of March 31, 2024, the Company had not yet commenced any operations. All activity through March 31, 2024 relates to the Company’s formation, the Initial Public Offering (as defined below) and after the Initial Public Offering, searching for a Business Combination target. The Company will not generate any operating revenues until after the completion of its Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the IPO (as defined below). The Company has selected December 31 as its fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

The Company’s sponsor is Wuren Fubao Inc., a Cayman Islands exempted company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on August 9, 2022. On August 12, 2022, the Company consummated its Initial Public Offering of 7,392,855 units (the “Units”, and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”), including the issuance of 892,855 Units as a result of the partial exercise by EF Hutton, division of Benchmark Investments, LLC (the “Representative”) of its over-allotment option (the “Over-Allotment Option”), at $10.00 per Unit, generating gross proceeds of $73,928,550 (the “Initial Public Offering” or “IPO”), and incurring offering costs of $3,898,030, of which $2,587,499 was for deferred underwriting commissions (see Note 6). As a result of the partial exercise of the Representative’s Over-Allotment Option, an aggregate of 20,536 founder shares were forfeited to the Company of which was reflected retroactively.

Simultaneously with the closing of the IPO, the Company consummated the private placement (“Private Placement”) with the Sponsor of 373,750 units (the “Private Units”), generating total proceeds of $3,737,500 (see Note 4).

Following the closing of the Initial Public Offering on August 12, 2022, an amount of $75,776,764 ($10.25 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Private Units was placed in a trust account (the “Trust Account”) and may be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below.

The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination. The Company will proceed with a business combination only if the Company have net tangible assets of at least $5,000,001 immediately prior to or upon such consummation and, solely if a vote is held to approve a business combination, an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the company.

The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.25 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per- share amount to be distributed to shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter. There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. These ordinary shares were recorded at a redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”

If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Memorandum and Articles of Association, offer such redemption pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination.

The Sponsor has agreed (a) to vote its founder shares, the ordinary shares included in the Private Units (the “Private Shares”) and any Public Shares purchased during or after the IPO in favor of a Business Combination, (b) not to propose an amendment to the Company’s Memorandum and Articles of Association with respect to the Company’s pre-Business Combination activities prior to the consummation of a Business Combination unless the Company provides dissenting public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment; (c) not to redeem any shares (including the Ordinary shares) and Private Units (including underlying securities) into the right to receive cash from the Trust Account in connection with a shareholder vote to approve a Business Combination (or to sell any shares in a tender offer in connection with a Business Combination if the Company does not seek shareholder approval in connection therewith) or a vote to amend the provisions of the Memorandum and Articles of Association relating to shareholders’ rights of pre-Business Combination activity and (d) that the Ordinary shares and Private Units (including underlying securities) shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated. However, the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased during or after the IPO if the Company fails to complete its Business Combination.

On August 9, 2023, the Company held an extraordinary general meeting of shareholders (the “Extraordinary General Meeting”), at which the Company’s shareholders approved the following proposals: (a) as a special resolution, giving the Company the right to extend the date by which the Company must consummate a business combination (the “Combination Period”) twelve (12) times for an additional one (1) month each time, from August 12, 2023 (i.e. the end of 12 months from the consummation of its Initial Public Offering, the “Termination Date”) to August 12, 2024 (the “Extended Date”), by depositing into the Trust Account the lesser of $100,000 or $0.045 per outstanding public share for each one-month extension (the “Extension Payment”) (the “Extension Amendment Proposal”) by deleting the amended and restated memorandum and articles of association (the “Articles of Association”) in its entirety and substitute it with the second amended and restated memorandum and articles of association of the Company (the “Amended Articles of Association”); (b) as an ordinary resolution, an amendment to the investment management trust agreement dated as of August 9, 2022 between the Company and Continental Stock Transfer & Trust Company (the “Trust Agreement”), to extend the Combination Period from the Termination Date to the Extended Date, by depositing into the Trust Agreement the Extension Payment (the “Trust Agreement Amendment Proposal”); and (c) as a special resolution, an amendment to the Articles of Association to remove the net tangible asset requirement from the Articles of Association in order to expand the methods that the Company may employ so as not to become subject to the “penny stock” rules of the Securities and Exchange Commission by deleting the Articles of Association in its entirety and substitute it with the second amended and restated memorandum and articles of association of the Company (the “NTA Requirement Amendment Proposal”). In connection with the shareholders’ vote at the Extraordinary General Meeting, 1,550,710 ordinary shares were tendered for redemption. On August 14, 2023, the Company accepted a reversal request for 109,819 shares. As a result, a total of 1,440,891 ordinary shares were redeemed at a redemption price of approximately $10.68 per share, for an aggregate redemption amount of $15,385,924, leaving 5,951,964 ordinary shares subject to possible redemption still outstanding after the August 2023 redemption.

In connection with the shareholders’ vote at the annual general meeting (“Annual General Meeting”) of shareholders held by the Company on October 20, 2023, 824,682 ordinary shares were tendered for redemption, leaving 5,127,282 ordinary shares subject to possible redemption still outstanding.

From August 2023 to December 2023, the Company deposited five tranches of $100,000, for an aggregated of $500,000 into the Trust Account, extending the Termination Date to January 12, 2024. From January 2024 to March 2024, the Company deposited additional three tranches of $100,000, for an aggregated of $300,000 into the Trust Account, extending the Termination Date to April 12, 2024. The Company has the right to extend the Combination Period four (4) more times for an additional one (1) month each time, from April 12, 2024 to August 12, 2024. On August 6, 2024, the Company deposited the required extension contributions of $400,000 into the Trust Account, to extend the Termination Date to August 12, 2024.

If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than five business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable and less interest to pay dissolution expenses up to $50,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the IPO price per Unit ($10.00).

The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below $10.25 per share, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the company’s independent registered accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

Liquidity and Capital Resources

As of March 31, 2024, the Company had $5,308 of cash in its operating bank account.

The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor to cover for certain offering costs on the Company’s behalf in exchange for issuance of Founder Shares (as defined in Note 5), and loan from the Sponsor of $159,478 under the Note (as defined in Note 5). Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering, the Private Placement held outside of the Trust Account, and the Convertible Promissory Notes (as defined and described in Note 5). As of March 31, 2024, there was $770,112 outstanding under the Convertible Promissory Notes for extension and working capital purposes.

Going Concern Consideration

The Company expects to incur significant costs in pursuit of its financing and acquisition plans. In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15,“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that if the Company is unsuccessful in consummating an Initial Business Combination by August 12, 2024, the requirement that the Company cease all operations, redeem the Public Shares and thereafter liquidate and dissolve raises substantial doubt about the Company’s ability to continue as a going concern. The balance sheet does not include any adjustments that might result from the outcome of this uncertainty. The accompanying financial statement has been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements are presented in U.S. Dollars and conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in the annual financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. The interim financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023, respectively, are unaudited. In the opinion of management, the interim financial statements include all adjustments, consisting only of normal recurring adjustments, necessary to provide a fair statement of the results for the interim periods. The accompanying balance sheet as of December 31, 2023, is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for fiscal the year ended December 31, 2023. The interim results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected through December 31, 2024 or for any future periods.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $5,308 in cash outside of trust account as of March 31, 2024 and December 31, 2023. The Company had no cash equivalents as of March 31, 2024 and December 31, 2023.

Investments Held in Trust Account

As of March 31, 2024 and December 31, 2023, substantially all of the assets held in the Trust Account were held in U.S. Treasury Securities Money Market Funds. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in investment income earned on investments held in Trust in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. As of March 31, 2024 and December 31, 2023, the estimated fair values of investments held in Trust Account was $57,266,630 and $56,231,052, respectively.

Fair Value of Financial Instruments

The Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

●

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

●

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

●

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of March 31, 2024 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value:


Description	Quoted Prices in Active Markets (Level 1)		Significant other Observable Inputs (Level 2)		Significant other Unobservable Inputs (Level 3)
Assets
Marketable securities held in trust account	$	57,266,630	$	-	$	-

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of December 31, 2023 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value:

Description

Quoted Prices in
Active Markets
(Level 1)

Significant other
Observable
Inputs

(Level 2)

Significant other
Unobservable
Inputs

(Level 3)

Assets

Marketable securities held in trust account

56,231,052

Offering Costs Associated with the Initial Public Offering

Offering costs consisted of legal, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. With the partial exercise of the over-allotment, offering cost amounted to $3,898,030 consisting of $739,286 of up-front underwriting fees and a deferred discount of $2,587,499 and $571,245 of other costs, were charged to additional paid-in capital upon completion of the Public Offering. For the year ended December 31, 2023, the Company charged $210,873 in offering costs to accumulated deficit.

Ordinary Shares Subject to Possible Redemption

As discussed in Note 3, all of the 7,392,855 ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s amended and restated certificate of incorporation. In accordance with ASC 480, conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. Ordinary liquidation events, which involve the redemption and liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480. In connection with the shareholders’ vote at the Extraordinary General Meeting on August 9, 2023, 1,550,710 ordinary shares were tendered for redemption. On August 14, 2023, the Company accepted a reversal request for 109,819 shares. As a result, a total of 1,440,891 ordinary shares were redeemed, leaving 5,951,964 ordinary shares subject to possible redemption after the August 7, 2023 redemption. In connection with the Annual General Meeting held on October 20, 2023, 824,682 ordinary shares were tendered for redemption, leaving 5,127,282 ordinary shares subject to possible redemption still outstanding. Accordingly, as of March 31, 2024 and December 31, 2023, 5,127,282 ordinary shares subject to possible redemption at the redemption amount were presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheets.

Income Taxes

The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits as of March 31, 2024 and December 31, 2023 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero from inception to March 31, 2024.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. As of March 31, 2024, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. As of March 31, 2024 and December 31, 2023, the Company had $5,308 cash held in operating bank account.

Net Income Per Share

Net income per share is computed by dividing net income by the weighted average number of ordinary shares outstanding for the period. The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the Initial Public Offering and warrants issued as components of the Private Placement Units (the “Private Warrants”) since the exercise of the warrants are contingent upon the occurrence of future events. As a result, diluted income per share is the same as basic income per share for the periods.

The following table reflects the calculation of basic and diluted net income per ordinary share:

Schedule of Basic and Diluted Net income Per Share


	For the three months ended March 31, 2024		For the three months ended March 31, 2023
Net income	$	307,277	$	694,054
Denominator: weighted average number of ordinary shares		7,423,175		9,688,748
Basic and diluted net income per ordinary share	$	0.04	$	0.07

Risks and Uncertainties

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, close of the Offering, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 3. INITIAL PUBLIC OFFERING

On August 12, 2022, the Company consummated its Initial Public Offering of 7,392,855 Units (including the issuance of 892,855 Units as a result of the underwriter’s partial exercise of its over-allotment option), at $10.00 per Unit, generating gross proceeds of $73,928,550.

Each Unit consists of one ordinary share, one warrant and one right. Each whole warrant entitles the holder thereof to purchase one ordinary share at a price of $11.50 per share, subject to adjustment as described in the IPO prospectus. Each right entitles the holder thereof to acquire one-eighth of one ordinary share (see Note 7).

As of August 12, 2022, the Company incurred offering costs of approximately $3,898,030, of which $2,587,499 was for deferred underwriting commissions. For the year ended December 31, 2023, the Company recorded $210,873 in offering costs and charged it to accumulated deficit.

NOTE 4. PRIVATE PLACEMENT

The proceeds from the sale of the Private Units were added to the net proceeds from the Offering held in the Trust Account. The Private Units are identical to the Units sold in the Initial Public Offering, except there will be no redemption rights or liquidating distributions from the Company’s trust account with respect to the private shares, which will expire worthless if the Company does not consummate a business combination. With respect to the private warrants (“Private Warrants”), as described in Note 7, the warrant agent shall not register any transfer of private warrants until after the consummation of an initial business. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Warrants will expire worthless.

NOTE 5. RELATED PARTY TRANSACTIONS

Founder Shares

During the period ended December 31, 2021, the Company issued an aggregate of 2,156,250 shares of Ordinary shares to the Sponsor for an aggregate purchase price of $25,000 in cash. On July 1, 2022, the sponsor surrendered an aggregate of 287,500 founder shares for no consideration, which surrender was effective retroactively, resulting in 1,868,750 shares being outstanding. On August 12, 2022, as a result of the partial exercise of the Representative’s Over-Allotment Option, an aggregate of 20,536 founder shares were further forfeited to the Company, which surrender was effective retroactively and resulting in 1,848,214 shares being outstanding, so that the Sponsor will collectively own 20% of the Company’s issued and outstanding shares after IPO (assuming the initial shareholders do not purchase any Public Shares in the IPO and excluding the Private Units and underlying securities).

Subject to certain limited exceptions, the initial shareholders have agreed not to transfer, assign or sell their founder shares until six months after the date of the consummation of our Business Combination or earlier if, subsequent to Business Combination, the Company consummate a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.

Due to Related Party

As of March 31, 2024 and December 31, 2023, the amounts due to related party was $62,260 and $54,535, respectively, for expenses paid by CFO on behalf of the Company. These amounts are unsecured, non-interest bearing and due on demand.

Convertible Promissory Notes

On September 8, 2023, the Company issued an unsecured promissory note (the “September 2023 Convertible Note”), effective as of September 8, 2023, in an amount of $10,000 to the Sponsor. The Convertible Promissory Note No.1 bears no interest and is repayable in full upon the consummation of the Company’s business combination. It is convertible at the Sponsor’s election upon the consummation of the Company’s business combination. Upon such election, the note will convert, at a price of $10.00 per unit, into units identical to the private placement units issued in connection with the Company’s Initial Public Offering.

On each of October 10, 2023, November 8, 2023 and December 14, 2024, the Company issued an unsecured promissory note (each is called “October 2023 Convertible Note”, “November 2023 Convertible Note” and “December 2023 Convertible Note”, respectively, collectively with September 2023 Convertible Note were called “Convertible Promissory Notes”) amounting to $100,000, $190,112 and $100,000, respectively, for an aggregated of $390,112, to the Company’s CFO. The Convertible Promissory Notes bear no interest and are repayable in full upon the consummation of the Company’s Business Combination. They are convertible at the Sponsor’s or CFO’s election upon the consummation of the Company’s Business Combination. Upon such election, the notes will convert, at a price of $10.00 per unit, into units identical to the private placement units issued in connection with the Company’s Initial Public Offering.

From January 2024 to March 31, 2024, the Company issued four unsecured promissory notes (together with the convertible promissory notes as described above, were called “Convertible Promissory Notes”) amounting to $100,000, $100,000 $100,000 and $70,000, respectively, for an aggregated of $370,000, to the Company's CFO. The Convertible Promissory Notes bear no interest and are repayable in full upon the consummation of the Company’s Business Combination. They are convertible at the CFO’s election upon the consummation of the Company’s Business Combination. Upon such election, the notes will convert, at a price of $10.00 per unit, into units identical to the private placement units issued in connection with the Company’s Initial Public Offering.

As of March 31, 2024, the Company has borrowed $770,112 under the Convertible Promissory Notes, of which $760,112 was issued to the Company’s CFO, and 10,000 was issued to the Sponsor.

As of December 31, 2024, the Company has borrowed $400,112 under the Convertible Promissory Notes, of which $390,112 was issued to the Company’s CFO, and $10,000 was issued to the Sponsor.

Working Capital Loans

In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of notes may be converted upon consummation of a Business Combination into additional Private Units at a price of $10.00 per Unit. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of March 31, 2024 and December 31, 2023, the Company borrowed $240,112 and $90,112 which was included in convertible promissory note – related party.

Office Space Provided by Sponsor

The Company currently maintain executive offices at 5186 Carroll Canyon Rd, San Diego, CA 92121. Such space was provided to the Company free of charge by the Sponsor.

NOTE 6. COMMITMENTS AND CONTINGENCIES

Registration Rights

The initial shareholders and their permitted transferees can demand that the Company register the founder shares, the private units and the underlying private shares and private warrants, and the units issuable upon conversion of working capital loans and the underlying ordinary shares, warrants and rights, pursuant to a Registration Rights Agreement signed on August 9, 2022. The holders of such securities are entitled to demand that the Company register these securities at any time after consummation of a Business Combination. Notwithstanding anything to the contrary, any holder that is affiliated with an underwriter participating in the Company’s IPO may only make a demand on one occasion and only during the five-year period beginning on the effective date of the registration statement. In addition, the holders have certain “piggy-back” registration rights on registration statements filed after our consummation of a business combination; provided that any holder that is affiliated with an underwriter participating in the Company’s IPO may participate in a “piggy-back” registration only during the seven-year period beginning on the effective date of the registration statement.

The underwriters purchased the 892,855 of additional Units to cover over-allotments, less the underwriting discounts and commissions.

The underwriters were entitled to a cash underwriting discount of one percent (1.00%) of the gross proceeds of the Offering, or $739,286 as the underwriters’ over-allotment is partially exercised. The underwriters are also entitled to a deferred fee of three point five percent (3.50%) of the gross proceeds of the Offering, or $2,587,499 as the underwriters’ over-allotment is partially exercised upon closing of the Business Combination. On March 4, 2024, the Company and the underwriters, entered into a satisfaction and discharge of indebtedness pursuant to underwriting agreement dated August 9, 2022 (the “Satisfaction and Discharge Agreement”), pursuant to which, the underwriter agrees to revise the deferred underwriting fee of $2,587,499, to (1) $750,000 in cash on the date of the closing of the initial business combination (the “Closing”) and (2) 200,000 of registered and unrestricted shares of the Company, shall be issued and delivered to the underwriter at the Closing. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. The Company evaluated the Satisfaction and Discharge Agreement and concluded that the share settlement portion of the Satisfaction and Discharge Agreement is representative of a share-based payment transaction in which the Company is acquiring services to be used within the Company’s operations and upon settlement agreeing to issue ordinary shares. In this case, the share settlement portion of the Satisfaction and Discharge Agreement is within the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the Satisfaction and Discharge Agreement executed date (the “Grant Date”). The Company used the public trading price of Class A ordinary shares at Grant Date to value the fair value of the Granted Shares. The fair value of the 200,000 Granted Shares was $2,216,000 in total, or $11.08 per share. The Satisfaction and Discharge Agreement was executed on March 4, 2024, the underwriter has provided service to the Company prior to closing of the IPO and the Company has recorded $1,837,499 deferred liability for the share settlement portion of the Satisfaction and Discharge Agreement at the closing of the IPO. The fair value of Granted Shares in excess of the liability settled, in the amount of $378,501, as a result of the Satisfaction and Discharge Agreement was recorded as loss on the modification of deferred underwriting commission in the accompanying unaudited statements of operations.

In addition, the Company paid the representative of the underwriters, at closing of the Initial Public Offering, 1.00% of the of the IPO shares in the Company’s ordinary shares or 73,929 ordinary shares as the underwriters’ over-allotment was partially exercised.

Right of First Refusal

For a period beginning on the closing of the Company’s IPO and ending 6 months from the closing of a business combination, the Company have granted EF Hutton, division of Benchmark Investments, LLC a right of first refusal to act as sole investment banker, sole book running manager and/or sole placement agent for any and all future private or public equity, equity-linked, convertible and debt offerings during such period. In accordance with FINRA Rule 5110(g)(6)(A), such right of first refusal shall not have a duration of more than three years from the commencement of sales in the Company’s IPO.

NOTE 7. STOCKHOLDERS’ DEFICIT

Ordinary Shares — The Company is authorized to issue 500,000,000 ordinary shares of with a par value of $0.0001 per share. Holders of the Company’s Ordinary shares are entitled to one vote for each share.

Prior to the offering, the Company issued 1,437,500 ordinary shares to our initial shareholders. On October 24, 2021, the Company declared a share dividend of 0.50 shares for each outstanding share, resulting in an aggregate of 2,156,250 founder shares being issued. The aggregate purchase price for the founder shares was $25,000.

On July 1, 2022, the sponsor surrendered an aggregate of 287,500 founder shares for no consideration, which surrender was effective retroactively, resulting in 1,868,750 shares being outstanding. On August 12, 2022, as a result of the partial exercise of the Representative’s Over-Allotment Option, an aggregate of 20,536 founder shares were further forfeited to the Company, which surrender was effective retroactively and resulting in 1,848,214 shares being outstanding and held by Sponsor.

As of March 31, 2024 and December 31, 2023, there were 2,295,893 ordinary shares issued and outstanding, excluding 5,127,282 ordinary shares subject to possible redemption, respectively.

Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants. The warrants will become exercisable 30 days after the completion of a Business Combination. No Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary share issuable upon exercise of the Warrants and a current prospectus relating to such ordinary share. Notwithstanding the foregoing, if a registration statement covering the ordinary share issuable upon the exercise of the Warrants is not effective within 90 days from the consummation of a Business Combination, the holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise the Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their Warrants on a cashless basis. The Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.

The Company may call the Warrants for redemption, in whole and not in part, at a price of $0.01 per warrant:

●

at any time while the Warrants are exercisable,

●

upon not less than 30 days’ prior written notice of redemption to each Warrant holder,

●

if, and only if, the reported last sale price of the ordinary share equals or exceeds $18 per share, for any 20 trading days within a 30-trading day period ending on the third trading day prior to the notice of redemption to Warrant holders, and

●

if, and only if, there is a current registration statement in effect with respect to the ordinary share underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.

The private warrants (including the ordinary shares issuable upon exercise of the private warrants) will not be transferable, assignable or salable until 30 days after the completion of our Business Combination and they will not be redeemable by the Company so long as they are held by the initial shareholders or their permitted transferees. The initial shareholders, or their permitted transferees, have the option to exercise the private warrants on a cashless basis.

If the Company calls the Warrants for redemption, management will have the option to require all holders that wish to exercise the Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary share issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger, or consolidation. However, the warrants will not be adjusted for issuances of ordinary share at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.

The Company accounts for 7,766,605 warrants issued in connection with the Initial Public Offering (comprised of 7,392,855 Public Warrants and 373,750 Private Warrants) (the “Warrants”) in accordance with the guidance contained in ASC 815-40 Derivatives and Hedging - Contracts in Entity’s Own Equity (“ASC 815”) under which the Warrants meet the criteria for equity treatment and was recorded as a component of additional paid-in capital at the time of issuance.

Rights — Each holder of a right will receive one-eighth (1/8) of one ordinary share upon consummation of a Business Combination, even if the holder of such right redeemed all shares held by it in connection with a Business Combination. No fractional shares will be issued upon exchange of the rights. No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares upon consummation of a Business Combination as the consideration related thereto has been included in the unit purchase price paid for by investors in the IPO. If the Company enters into a definitive agreement for a Business Combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the ordinary share will receive in the transaction on an as- converted into ordinary share basis and each holder of a right will be required to affirmatively convert its rights in order to receive 1/8 share underlying each right (without paying additional consideration). The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company).

Additionally, in no event will the Company be required to net cash settle the rights. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights. Accordingly, the rights may expire worthless.

NOTE 8. SUBSEQUENT EVENTS

Debt Financing for Working Capital and Extension

For the period from April 1, 2024 though the filing the Company borrowed $81,000 from the Company’s CFO, in form of convertible promissory note, for working capital purpose. These loans bear no interest and are repayable in full upon the consummation of the Company’s Business Combination. They are convertible at the CFO’s election upon the consummation of the Company’s Business Combination. Upon such election, these loans will convert, at a price of $10.00 per unit, into units identical to the private placement units issued in connection with the Company’s initial public offering.

For the period from April 1, 2024 though the filing, the CFO paid $81,800 to third-party vendors, on behalf of the Company, which will be recorded as due to related party. These amounts are unsecured, non-interest bearing and due on demand. Up to the date that the unaudited financial statements were issued, the total amount due to the related party was $144,060.

Subsequent to March 31, 2024, and through the date these unaudited financial statements were issued, the Company borrowed $300,000 from an unrelated third party. These amounts are unsecured, non-interest bearing and due on demand.

On August 5, 2024, the Company borrowed $300,000 from another unrelated third party, by issuing a promissory note. The unpaid principal balance of this note bears an annual interest rate of nine point one two seven percent (9.127%) per annum. The note will be due two months after executed. On August 6, 2024, the Company received the $300,000 in full under such note.

On August 6, 2024, using the amounts raised from the third parties, the Company deposited $400,000 into Trust Account, extending the Termination Date to August 12, 2024.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References to the “Company,” “Embrace Change,” “our,” “us” or “we” refer to Embrace change Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited interim financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward- looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other U.S. Securities and Exchange Commission (“SEC”) filings.

Overview

We are a blank check company incorporated in the Cayman Islands for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We intend to effectuate our Business Combination using cash from the proceeds of the initial public offering (the “IPO”) and the private placement of the private placement units, the proceeds of the sale of our securities in connection with our Business Combination, our shares, debt or a combination of cash, stock and debt.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.

Recent Developments

On August 9, 2023, the Company held an extraordinary general meeting of shareholders (the “Extraordinary General Meeting”), at which the Company’s shareholders approved the following proposals: (a) as a special resolution, giving the Company the right to extend the date by which the Company must consummate a business combination (the “Combination Period”) twelve (12) times for an additional one (1) month each time, from August 12, 2023 (i.e. the end of 12 months from the consummation of its initial public offering, the “Termination Date”) to August 12, 2024 (the “Extended Date”), by depositing into the trust account (the “Trust Account”) the lesser of $100,000 or $0.045 per outstanding public share for each one-month extension (the “Extension Payment”) (the “Extension Amendment Proposal”) by deleting the amended and restated memorandum and articles of association (the “Articles of Association”) in its entirety and substitute it with the second amended and restated memorandum and articles of association of the Company (the “Amended Articles of Association”); (b) as an ordinary resolution, an amendment to the investment management trust agreement dated as of August 9, 2022 between the Company and Continental Stock Transfer & Trust Company (the “Trust Agreement”), to extend the Combination Period from the Termination Date to the Extended Date, by depositing into the Trust Agreement the Extension Payment (the “Trust Agreement Amendment Proposal”); and (c) as a special resolution, an amendment to the Articles of Association to remove the net tangible asset requirement from the Articles of Association in order to expand the methods that the Company may employ so as not to become subject to the “penny stock” rules of the Securities and Exchange Commission by deleting the Articles of Association in its entirety and substitute it with the second amended and restated memorandum and articles of association of the Company (the “NTA Requirement Amendment Proposal”). In connection with the shareholders’ vote at the Extraordinary General Meeting, 1,550,710 ordinary shares were tendered for redemption. On August 14, 2023, the Company accepted a reversal request for 109,819 shares. As a result, a total of 1,440,891 ordinary shares were redeemed at a redemption price of approximately $10.68 per share, for an aggregate redemption amount of $15,385,924, leaving 5,951,964 ordinary shares subject to possible redemption outstanding after the August 2023 redemption.

On October 20, 2023, the Company held an annual general meeting of shareholders (the “Annual General Meeting”), at which the Company’s shareholders approved to amend the Amended Articles of Association by removing the restriction of the Company to undertake a Business Combination with any entity or business based in, or with its principal or a majority of its business operations (either directly or through any subsidiaries) in, the People’s Republic of China (including Hong Kong and Macau). In connection with the Annual General Meeting, holders of 824,682 ordinary shares of the Company properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.81 per share, for an aggregate redemption amount of $8,911,074, leaving 5,127,282 ordinary shares subject to possible redemption still outstanding as of March 31, 2024.

From August 2023 to March 2024, using the funds held outside the trust account and the proceeds from Convertible Promissory Notes (as described below), the Company made eight tranches of deposits of $100,000, for an aggregate of $800,000, to the Trust Account and extended the Combination Period from August 12, 2023 to April 12, 2024. The Company has the right to extend the Combination Period four (4) more times for an additional one (1) month each time, from April 12, 2024 to August 12, 2024. On August 6, 2024, the Company deposited the required extension contributions of $400,000 into the Trust Account, extending the Termination Date to August 12, 2024.

Commencing on August 9, 2022, we have agreed to pay ARC Group Limited, our sponsor’s financial advisor, a total of $10,000 per month for utilities and secretarial and administrative support. In October 2023, the Company and ARC Group Limited terminated the administrative support agreement. As of March 31, 2024, the unpaid balance of $40,000 was reflected as accrued expenses on the balance sheet.

On October 12, 2023, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with Listing Rule 5450(a)(2) of The Nasdaq Global Market in connection with its listing of the Company’s ordinary shares, par value $0.001 per share, which requires the Company to maintain a minimum of 400 total holders of its ordinary shares for continued listing on The Nasdaq Global Market. The notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on The Nasdaq Global Market. The notice states that the Company has until November 27, 2023 to submit a plan to regain compliance with Listing Rule 5450(a)(2). If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an extension of up to 180 calendar days from October 12, 2023, the date of the Notice, to evidence compliance with Listing Rule 5450(a)(2). If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal Nasdaq’s determination. Alternatively, the Company may consider applying for a transfer to The Nasdaq Capital Market. In order to transfer, the Company must submit an on-line transfer application, pay the $5,000 application fee, and meet The Nasdaq Capital Market’s continued listing requirements. The Company submitted a compliance plan to Nasdaq on November 27, 2023.

On December 22, 2023, the Company received a notification from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as it had failed to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”). Under the Nasdaq Listing Rules, the Company now has 60 calendar days to submit a plan to regain compliance and if the plan is accepted, Nasdaq may grant an exception of up to 180 calendar days from the Form 10-Q’s due date, or until May 20, 2024, to regain compliance. The Company later filed the Form 10-Q on March 1, 2024.

On March 4, 2024, the Company and EF Hutton entered into a Satisfaction and Discharge of Indebtedness Pursuant to Underwriting Agreement dated August 9, 2022 (the “Satisfaction and Discharge Agreement”), pursuant to which, EF Hutton agrees to revise the deferred underwriting fee of three point five percent (3.50%) of the gross proceeds of the initial public offering, or $2,587,499, to (1) $750,000 in cash on the date of the closing of the initial business combination (the “Closing”) and (2) 200,000 of registered and unrestricted shares of the Company, shall be issued and delivered to EF Hutton at the Closing.

On April 23, 2024, the Company received a delisting determination letter from the Listing Qualifications of Nasdaq advising the Company that the Company has not paid its assessed fees required by Listing Rule 5250(f). The Company subsequently paid the outstanding fee.

On May 30, 2024, the Company received a delinquency notification letter from Nasdaq due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024.

On June 24, 2024, the Company received a notice from Nasdaq indicating that, unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”) by 4:00 p.m. Eastern Time on July 1, 2024, the Company’s securities (units, ordinary shares, warrants, and rights) would be subject to suspension and delisting from The Nasdaq Global Market at the opening of business on July 3, 2024, due to the Company’s non-compliance with the Minimum Holders Rule and the Reporting Rule. The Company timely requested a hearing before the Panel to appeal the Staff Determination and submitted a request for extension of stay. The suspension referenced in the Staff Determination has been stayed for a period of 15 calendar days until July 16, 2024 and the hearing has been scheduled on August 1, 2024.

On July 12, 2024, the Company submitted a written submission to Nasdaq. On July 25, 2024, the Company received a notice from Nasdaq indicating the grant of the Company’s request to extend the stay of suspension pending a hearing on August 1, 2024, and issuance of a final Panel decision. On August 1, 2024, the Company attended the Nasdaq hearing before the Panel.

In July 2024, the Company borrowed $300,000 from an unrelated third party. These amounts are unsecured, non-interest bearing and due on demand.

On July 31, 2024, the Company filed a definitive proxy statement in connection with soliciting the shareholders approval on extension, among other matters. The shareholders meeting is scheduled to be held on August 12, 2024.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities, those necessary to prepare for our IPO and after our IPO, searching for a business combination target. Following our IPO, we will not generate any operating revenues until after completion of our Business Combination. We will generate non-operating income in the form of interest income on cash and cash equivalents after our IPO. There has been no significant change in our financial or trading position and no material adverse change has occurred since the date of our audited financial statements. We expect that we will incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with completing a business combination.

For the three months ended March 31, 2024, we had a net income of $357,077 which consists of investment income earned on investments held in trust account of $735,578 partially offset by operating costs of $49,800 and loss on modification of deferred underwriter commission of $378,501. For the three months ended March 31, 2023, we had a net income of $694,054, which consists of investment income earned on investments held in trust account of $822,317, partially offset by operating costs of $128,263.

Liquidity and Capital Resources

On August 12, 2022, the Company consummated its initial public offering of 7,392,855 units (the “Units”, and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”), including the issuance of 892,855 Units as a result of the partial exercise by EF Hutton, division of Benchmark Investments, LLC (the “Representative”) of its over-allotment option (the “Over-Allotment Option”), at $10.00 per Unit, generating gross proceeds of $73,928,550 (the “Initial Public Offering”).

Transaction costs of the Initial Public Offering with the exercise of the over-allotment amounted to $3,898,030 consisting of $739,286 of up-front underwriting fees and a deferred discount of $2,587,499 and $571,245 of other costs. As of closing, $760,003 of the proceeds from the IPO was held outside of the Trust Account and is available for working capital purposes. For the year ended December 31, 2023, the Company charged $210,873 in offering cost to accumulated deficit.

As of March 31, 2024, we had cash of $5,308 on our balance sheet and a working capital deficit of $1,876,397. We intend to use the funds held outside of the Trust Account and proceeds from Convertible Promissory Notes (as described below) for identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the Business Combination. The interest income earned on the investments in the Trust Account are unavailable to fund operating expenses.

In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of notes may be converted upon consummation of a Business Combination into additional Private Units at a price of $10.00 per Unit. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of March 31, 2024 and December 31, 2023, the Company borrowed $240,112 and $90,112, respectively, which was included in convertible promissory note - related party.

On September 8, 2023, the Company borrowed $10,000 from the Sponsor. The loan bears no interest and is repayable in full upon the consummation of the Company’s Business Combination. It is convertible at the Sponsor’s election upon the consummation of the Company’s Business Combination. Upon such election, this loan will convert, at a price of $10.00 per unit, into units identical to the private placement units issued in connection with the Company’s initial public offering.

From October 2023 to the filing of this Quarterly Report, the Company borrowed $841,112 in total from our Chief Financial Officer, in form of convertible promissory notes, for working capital and extension deposits purposes (as described in Note 5 of the Notes to the Financial Statements). These loans bear no interest and are repayable in full upon the consummation of the Company’s Business Combination. They are convertible at the CFO’s election upon the consummation of the Company’s Business Combination. Upon such election, these loans will convert, at a price of $10.00 per unit, into units identical to the private placement units issued in connection with the Company’s initial public offering.

From October 2023 to the filing of this Quarterly Report, the Company’s CFO also paid $144,060, on behalf of us, to the third-party vendors for working capital purposes. These amounts are unsecured, non interest bearing and due on demand.

Off-Balance Sheet Financing Arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of March 31, 2024. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities. The underwriter is entitled to a deferred fee of three point five percent (3.50%) of the gross proceeds of the Offering upon closing of the Business Combination, or $2,587,499. On March 4, 2024, we and the underwriter, entered into a satisfaction and discharge of indebtedness pursuant to underwriting agreement dated August 9, 2022 (the “Satisfaction and Discharge Agreement”), pursuant to which, the underwriter agrees to revise the deferred underwriting fee of $2,587,499, to (1) $750,000 in cash on the date of the closing of the initial business combination (the “Closing”) and (2) 200,000 of registered and unrestricted shares of us, shall be issued and delivered to the underwriter at the Closing. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement.

Critical Accounting Estimates

The preparation of audited financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the audited financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. As of March 31, 2024, there were no critical accounting estimates.

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited financial statements.

Off-Balance Sheet Arrangements; Commitments and Contractual Obligations; Quarterly Results

As of the date of this report, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of

Regulation S-K and did not have any commitments or contractual obligations. No unaudited quarterly operating data is included in this report as we have conducted no operations to date.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company we are not required to make disclosures under this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the fiscal quarter ended March 31, 2024, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that during the period covered by this report, our disclosure controls and procedures were not effective.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended March 31, 2024, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

Factors that could cause our actual results to differ materially from those in this Quarterly Report include the risk factors described in the registration statements on Form S-1 (File Nos. 333-258221 and 333-265184) for our IPO filed with the SEC. As of the date of this Quarterly Report, there have been no material changes to the previously disclosed risk factors.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We issued an aggregate of 1,437,500 ordinary shares to certain of our initial shareholders on April 20, 2022. We subsequently declared a share dividend of 0.50 shares for each outstanding share, resulting in 2,156,250 founder shares being outstanding. On July 1, 2022, the sponsor surrendered an aggregate of 287,500 founder shares for no consideration, which surrender was effective retroactively, resulting in 1,868,750 shares being outstanding. As a result of the partial exercise of the representative’s over-allotment option, an aggregate of 20,536 founder shares were forfeited to us, which surrender was effective retroactively and resulting in an aggregate of 1,848,214 founder shares issued and outstanding. The foregoing issuance was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (“Securities Act”).

On August 12, 2022, we consummated our IPO of units (the “Units”), including the issuance of 892,855 Units as a result of the partial exercise of the representative’s over-allotment option. The Units issued in the IPO were sold at an offering price of $10.00 per Unit, generating total gross proceeds of $73,928,550. EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”), acted as the sole book-running manager for the IPO. US Tiger Securities, Inc. acted as the co-manager for the IPO. The securities in the IPO were registered under the Securities Act on two registration statements on Form S-1 (File Nos. 333-258221 and 333-265184) (as amended, the “Registration Statement”). The Securities and Exchange Commission declared the registration statements effective on May 16, 2022 and August 9, 2022, respectively.

Simultaneous with the consummation of the IPO, we consummated the private placement (“Private Placement”) with the sponsor of 373,750 units (the “Private Units”), generating total proceeds of $3,737,500. The Private Units are identical to the Units sold in the IPO except that the holder has agreed not to transfer, assign, or sell any of the Private Units or underlying securities (except in limited circumstances, as described in the Registration Statement) until the completion of the Company’s initial business combination. In addition, the warrants included in the Private Units are not redeemable if held by them or a permitted transferee. The sponsor was granted certain demand and piggy-back registration rights in connection with the purchase of the Private Units. The issuance was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

On August 12, 2022, a total of $75,776,764 of the net proceeds from the IPO and the Private Placement were deposited in a trust account established for the benefit of the public shareholders. This includes $72,039,264 of the net proceeds from the IPO (which amount includes $2,587,499 of the underwriters’ deferred discount) and $3,737,500 from the Private Placement.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits.

Exhibit Number		Description
31.1*		Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) Pursuant to Rules 13a-14(a) and 15d- 14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 7, 2024	EMBRACE CHANGE ACQUISITION CORP.

	By:	/s/ Zheng Yuan
	Name:	Zheng Yuan
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

Exhibit 31.1

CERTIFICATION

PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jingyu Wang, certify that:

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 of Embrace Change Acquisition Corp.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: August 7, 2024

By:

/s/ Jingyu Wang

Jingyu Wang

Chief Executive Officer and Director

(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION

PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Zheng Yuan, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 of Embrace Change Acquisition Corp.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

5.	The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: August 7, 2024	By:	/s/ Zheng Yuan
		Zheng Yuan
		Chief Financial Officer and Director
		(Principal Financial and Accounting Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Embrace Change Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jingyu Wang, Chief Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 7, 2024	/s/ Jingyu Wang
	Name:	Jingyu Wang
	Title:	Chief Executive Officer and Director
		(Principal Executive Officer)

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Embrace Change Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Zheng Yuan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 7, 2024	/s/ Zheng Yuan
	Name:	Zheng Yuan
	Title:	Chief Financial Officer and Director
		(Principal Financial and Accounting Officer)

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	Jul. 30, 2024
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-41397
Entity Registrant Name	EMBRACE CHANGE ACQUISITION CORP.
Entity Central Index Key	0001869601
Entity Tax Identification Number	00-0000000
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	5186 Carroll Canyon Rd
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	(858)
Local Phone Number	688-4965
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		7,423,175
Units, each consisting of one ordinary share, one right and one warrant
Title of 12(b) Security	Units, each consisting of one ordinary share, one right and one warrant
Trading Symbol	EMCGU
Security Exchange Name	NASDAQ
Ordinary Shares
Title of 12(b) Security	Ordinary Shares
Trading Symbol	EMCG
Security Exchange Name	NASDAQ
Rights [Member]
Title of 12(b) Security	Rights
Trading Symbol	EMCGR
Security Exchange Name	NASDAQ
Warrants
Title of 12(b) Security	Warrants
Trading Symbol	EMCGW
Security Exchange Name	NASDAQ

BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
ASSETS
Cash	$ 5,308	$ 5,308
Total Current Assets	5,308	5,308
Marketable securities held in trust account	57,266,630	56,231,052
Total assets	57,271,938	56,236,360
Current liabilities
Accrued expenses	1,049,333	1,077,258
Due to related party	62,260	54,535
Convertible promissory note – related party	770,112	400,112
Total current liabilities	1,881,705	1,531,905
Deferred underwriter fee payable	2,966,000	2,587,499
Total liabilities	4,847,705	4,119,404
Ordinary shares subject to possible redemption, 5,127,282 and 5,127,282 shares issued and outstanding at redemption value of $11.17 per share and $10.97 per share as of March 31, 2024 and December 31, 2023, respectively	57,266,630	56,231,052
Stockholders’ Deficit
Ordinary Shares, par value $0.0001; 500,000,000 shares authorized; 2,295,893 (excluding 5,127,282 and 5,127,282 shares subject to redemption, respectively) issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	230	230
Additional paid-in capital
Accumulated deficit	(4,842,627)	(4,114,326)
Total Stockholders’ Deficit	(4,842,397)	(4,114,096)
Total Liabilities and Stockholders’ Deficit	$ 57,271,938	$ 56,236,360

BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Temporary equity, shares issued	5,127,282	5,127,282
Temporary equity, shares outstanding	5,127,282	5,127,282
Temporary equity, redemption price per share	$ 11.17	$ 10.97
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares, issued	2,295,893	2,295,893
Common stock, shares, outstanding	2,295,893	2,295,893

STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Formation and operating costs	$ 49,800	$ (128,263)
Loss from operations	(49,800)	(128,263)
Other income (loss):
Investment income earned on investments held in Trust Account	735,578	822,317
Loss on modification of deferred underwriting commission	(378,501)
Total other income (loss)	357,077	822,317
Net income	$ 307,277	$ 694,054
Weighted average shares outstanding, basic and diluted	7,423,175	9,688,748
Basic and diluted net income per ordinary share	$ 0.04	$ 0.07

STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)	Common Stock [Member]	Retained Earnings [Member]	Total
Balance – December 31, 2022 at Dec. 31, 2022	$ 230	$ (2,341,247)	$ (2,341,017)
Beginning balance, shares at Dec. 31, 2022	2,295,893
Re-measurement of ordinary shares subject to redemption		(822,317)	(822,317)
Net income		694,054	694,054
Balance – March 31, 2023 at Mar. 31, 2023	$ 230	(2,469,510)	(2,469,280)
Ending balance, shares at Mar. 31, 2023	2,295,893
Balance – December 31, 2022 at Dec. 31, 2023	$ 230	(4,114,326)	(4,114,096)
Beginning balance, shares at Dec. 31, 2023	2,295,893
Amount deposited into trust account subject to redemption		(300,000)	(300,000)
Re-measurement of ordinary shares subject to redemption		(735,578)	(735,578)
Net income		307,277	307,277
Balance – March 31, 2023 at Mar. 31, 2024	$ 230	$ (4,842,627)	$ (4,842,397)
Ending balance, shares at Mar. 31, 2024	2,295,893

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Cash flow from operating activities:

Net income

$ 307,277

$ 694,054

Adjustments to reconcile net income to net cash used in operating activities:

Investment income earned on investments held in Trust Account

(735,578)

(822,317)

Loss on modification of deferred underwriting commission

378,501

Changes in operating assets and liabilities:

Other receivables

521

Accounts payable and accrued expenses

(27,925)

123,213

Net cash used in operating activities

(77,725)

(4,529)

Cash flows from investing activities:

Investment of cash in Trust Account

(300,000)

Net cash used in investing activities

(300,000)

Cash flow from financing activities:

Proceeds from convertible promissory note - related party

370,000

Proceeds from related party for working capital purpose

7,725

Net cash provided by financing activities

377,725

Net change in cash

(0)

(4,529)

Cash at the beginning of the period

5,308

403,012

Cash at the end of the period

5,308

398,483

Supplemental disclosure of non-cash financing activities:

Deferred underwriting fee payable

378,501

Re-measurement of ordinary shares subject to redemption

^[1]

735,578

822,317

Extension funds attributable to ordinary shares to redemption

$ 300,000

[1]	The value of ordinary share subject to redemption was re-measured with investment income earned on investments held in Trust Account.

DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

Liquidity and Capital Resources

As of March 31, 2024, the Company had $5,308 of cash in its operating bank account.

Going Concern Consideration

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Use of Estimates

Emerging Growth Company

Cash and Cash Equivalents

Investments Held in Trust Account

Fair Value of Financial Instruments

●

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

●


Description	Quoted Prices in Active Markets (Level 1)		Significant other Observable Inputs (Level 2)		Significant other Unobservable Inputs (Level 3)
Assets
Marketable securities held in trust account	$	57,266,630	$	-	$	-

Description

Quoted Prices in
Active Markets
(Level 1)

Significant other
Observable
Inputs

(Level 2)

Significant other
Unobservable
Inputs

(Level 3)

Assets

Marketable securities held in trust account

56,231,052

Offering Costs Associated with the Initial Public Offering

Ordinary Shares Subject to Possible Redemption

Income Taxes

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Concentration of Credit Risk

Net Income Per Share

The following table reflects the calculation of basic and diluted net income per ordinary share:

Schedule of Basic and Diluted Net income Per Share


	For the three months ended March 31, 2024		For the three months ended March 31, 2023
Net income	$	307,277	$	694,054
Denominator: weighted average number of ordinary shares		7,423,175		9,688,748
Basic and diluted net income per ordinary share	$	0.04	$	0.07

Risks and Uncertainties

INITIAL PUBLIC OFFERING

3 Months Ended

Mar. 31, 2024

Initial Public Offering

INITIAL PUBLIC OFFERING

NOTE 3. INITIAL PUBLIC OFFERING

PRIVATE PLACEMENT

3 Months Ended

Mar. 31, 2024

Private Placement

PRIVATE PLACEMENT

NOTE 4. PRIVATE PLACEMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2024

RELATED PARTY TRANSACTIONS

NOTE 5. RELATED PARTY TRANSACTIONS

Founder Shares

Due to Related Party

Convertible Promissory Notes

As of March 31, 2024, the Company has borrowed $770,112 under the Convertible Promissory Notes, of which $760,112 was issued to the Company’s CFO, and 10,000 was issued to the Sponsor.

As of December 31, 2024, the Company has borrowed $400,112 under the Convertible Promissory Notes, of which $390,112 was issued to the Company’s CFO, and $10,000 was issued to the Sponsor.

Working Capital Loans

Office Space Provided by Sponsor

The Company currently maintain executive offices at 5186 Carroll Canyon Rd, San Diego, CA 92121. Such space was provided to the Company free of charge by the Sponsor.

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 6. COMMITMENTS AND CONTINGENCIES

Registration Rights

The underwriters purchased the 892,855 of additional Units to cover over-allotments, less the underwriting discounts and commissions.

Right of First Refusal

STOCKHOLDERS’ DEFICIT

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

STOCKHOLDERS’ DEFICIT

NOTE 7. STOCKHOLDERS’ DEFICIT

As of March 31, 2024 and December 31, 2023, there were 2,295,893 ordinary shares issued and outstanding, excluding 5,127,282 ordinary shares subject to possible redemption, respectively.

The Company may call the Warrants for redemption, in whole and not in part, at a price of $0.01 per warrant:

●

at any time while the Warrants are exercisable,

●

upon not less than 30 days’ prior written notice of redemption to each Warrant holder,

●

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 8. SUBSEQUENT EVENTS

Debt Financing for Working Capital and Extension

On August 6, 2024, using the amounts raised from the third parties, the Company deposited $400,000 into Trust Account, extending the Termination Date to August 12, 2024.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Emerging Growth Company

Emerging Growth Company

Cash and Cash Equivalents

Cash and Cash Equivalents

Investments Held in Trust Account

Investments Held in Trust Account

Fair Value of Financial Instruments

Fair Value of Financial Instruments

●

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

●


Description	Quoted Prices in Active Markets (Level 1)		Significant other Observable Inputs (Level 2)		Significant other Unobservable Inputs (Level 3)
Assets
Marketable securities held in trust account	$	57,266,630	$	-	$	-

Description

Quoted Prices in
Active Markets
(Level 1)

Significant other
Observable
Inputs

(Level 2)

Significant other
Unobservable
Inputs

(Level 3)

Assets

Marketable securities held in trust account

56,231,052

Offering Costs Associated with the Initial Public Offering

Offering Costs Associated with the Initial Public Offering

Ordinary Shares Subject to Possible Redemption

Ordinary Shares Subject to Possible Redemption

Income Taxes

Income Taxes

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Concentration of Credit Risk

Concentration of Credit Risk

Net Income Per Share

Net Income Per Share

The following table reflects the calculation of basic and diluted net income per ordinary share:

Schedule of Basic and Diluted Net income Per Share


	For the three months ended March 31, 2024		For the three months ended March 31, 2023
Net income	$	307,277	$	694,054
Denominator: weighted average number of ordinary shares		7,423,175		9,688,748
Basic and diluted net income per ordinary share	$	0.04	$	0.07

Risks and Uncertainties

Risks and Uncertainties

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Summary of Fair Value, Assets Measured on Recurring Basis


Description	Quoted Prices in Active Markets (Level 1)		Significant other Observable Inputs (Level 2)		Significant other Unobservable Inputs (Level 3)
Assets
Marketable securities held in trust account	$	57,266,630	$	-	$	-

Description

Quoted Prices in
Active Markets
(Level 1)

Significant other
Observable
Inputs

(Level 2)

Significant other
Unobservable
Inputs

(Level 3)

Assets

Marketable securities held in trust account

56,231,052

Summary of Basic and Diluted Net Loss Per Share


	For the three months ended March 31, 2024		For the three months ended March 31, 2023
Net income	$	307,277	$	694,054
Denominator: weighted average number of ordinary shares		7,423,175		9,688,748
Basic and diluted net income per ordinary share	$	0.04	$	0.07

DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 14, 2023	Aug. 09, 2023	Aug. 12, 2022	Oct. 20, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2021	Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Incurred offering costs			$ 3,898,030		$ 3,898,030
Deferred underwriter fee payable non current			$ 2,587,499		2,587,499
forfeited shares			20,536
Payments to acquire restricted investments		$ 100,000	$ 75,776,764		300,000
Restricted Investment Price Per Share			10.25
Net tangible assets required for consummation of business combination					$ 5,000,001
Share Price					$ 10.25
Description of business combination period		must consummate a business combination (the “Combination Period”) twelve (12) times for an additional one (1) month each time, from August 12, 2023 (i.e. the end of 12 months from the consummation of its Initial Public Offering, the “Termination Date”) to August 12, 2024 (the “Extended Date”)
Stock Redeemed		1,550,710
Redemption price					$ 11.17			$ 10.97
Temporary equity, shares outstanding					5,127,282			5,127,282
Description of business organization					From August 2023 to December 2023, the Company deposited five tranches of $100,000, for an aggregated of $500,000 into the Trust Account, extending the Termination Date to January 12, 2024. From January 2024 to March 2024, the Company deposited additional three tranches of $100,000, for an aggregated of $300,000 into the Trust Account, extending the Termination Date to April 12, 2024. The Company has the right to extend the Combination Period four (4) more times for an additional one (1) month each time, from April 12, 2024 to August 12, 2024. On August 6, 2024, the Company deposited the required extension contributions of $400,000 into the Trust Account, to extend the Termination Date to August 12, 2024.
Dissolution expense					$ 50,000
Cash					5,308			$ 5,308
Repayments of related party debt						$ 159,478
Convertible Note [Member]
Subsidiary, Sale of Stock [Line Items]
Convertible debt current					$ 770,112
U S Government Securities [Member]
Subsidiary, Sale of Stock [Line Items]
Restricted Investments Term					185 days
Sponsor [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued							2,156,250
Number of shares issued for services, value					$ 25,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock Redeemed	1,440,891	1,550,710		824,682
Reversal of shares during the period	109,819
Redemption price	$ 10.68
Redemption amount	$ 15,385,924
Temporary equity, shares outstanding	5,951,964			5,127,282
Public Share [Member]
Subsidiary, Sale of Stock [Line Items]
Shares Issued, Price Per Share		$ 0.045
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Shares Issued, Price Per Share			$ 10.00
Proceeds from Issuance Initial Public Offering			$ 73,928,550
Share Price			$ 10.00
IPO [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued			7,392,855
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued			892,855
Private Placement [Member] \| Sponsor [Member]
Subsidiary, Sale of Stock [Line Items]
Class of warrants and rights issued during the period			373,750
Proceeds from issuance of warrants			$ 3,737,500

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Fair Value, Recurring [Member] - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto Asset [Line Items]
Marketable securities held in trust account	$ 57,266,630	$ 56,231,052
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto Asset [Line Items]
Marketable securities held in trust account
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto Asset [Line Items]
Marketable securities held in trust account

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accounting Policies [Abstract]
Net income	$ 307,277	$ 694,054
Denominator: weighted average number of ordinary shares	7,423,175	9,688,748
Basic and diluted net income per ordinary share	$ 0.04	$ 0.07

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended
	Aug. 14, 2023	Aug. 09, 2023	Aug. 12, 2022	Oct. 20, 2023	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Cash					$ 5,308	$ 5,308
Cash Equivalents, at Carrying Value					0	0
Investments held in Trust Account					57,266,630	$ 56,231,052
Incurred offering costs			$ 3,898,030		3,898,030
Deferred underwriter fee payable non current			$ 2,587,499		2,587,499
Additional paid-in capital					571,245
Accretion of offering costs to deficit					$ 210,873
Temporary equity, shares outstanding							7,392,855
Stock Redeemed		1,550,710
Temporary equity, shares outstanding					5,127,282	5,127,282
Unrecognized tax benefits					$ 0
Accrued interest and penalties					0	$ 0
Cash, FDIC insured amount					250,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock Redeemed	1,440,891	1,550,710		824,682
Reversal of shares during the period	109,819
Temporary equity, shares outstanding	5,951,964			5,127,282
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Payments for Underwriting Expense					$ 739,286

INITIAL PUBLIC OFFERING (Details Narrative) - USD ($)		3 Months Ended
INITIAL PUBLIC OFFERING (Details Narrative) - USD ($)	Aug. 12, 2022	Mar. 31, 2024	Dec. 31, 2023
Share price		$ 10.25
Incurred offering costs	$ 3,898,030	$ 3,898,030
Deferred underwriter fee payable non current	$ 2,587,499	2,966,000	$ 2,587,499
Accretion of offering costs to deficit		$ 210,873
Public Warrants [Member] \| Common Class A [Member]
Share price	$ 11.50
IPO [Member]
Share price	$ 10.00
Proceeds from issuance initial public offering	$ 73,928,550
IPO [Member] \| Common Stock [Member]
Number of shares issued	7,392,855
Over-Allotment Option [Member]
Number of shares issued	892,855

PRIVATE PLACEMENT (Details Narrative) - Private Placement Warrants [Member]	3 Months Ended
	Mar. 31, 2024 USD ($) shares
Subsidiary, Sale of Stock [Line Items]
Class of warrants and rights issued during the period \| shares	373,750
Proceeds from Issuance of private placement \| $	$ 3,737,500

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended	12 Months Ended
	Aug. 12, 2022	Jul. 01, 2022	Oct. 24, 2021	Mar. 31, 2024	Dec. 31, 2021	Dec. 31, 2023	Nov. 30, 2023	Oct. 31, 2023	Sep. 30, 2023	Sep. 08, 2023
Related Party Transaction [Line Items]
Temporary equity, shares outstanding				5,127,282		5,127,282
Common stock, shares, outstanding				2,295,893		2,295,893
Due to related party				$ 62,260		$ 54,535
Convertible promissory notes						100,000	$ 190,112	$ 100,000
Related party transaction description				From January 2024 to March 31, 2024, the Company issued four unsecured promissory notes (together with the convertible promissory notes as described above, were called “Convertible Promissory Notes”) amounting to $100,000, $100,000 $100,000 and $70,000, respectively, for an aggregated of $370,000, to the Company's CFO. The Convertible Promissory Notes bear no interest and are repayable in full upon the consummation of the Company’s Business Combination. They are convertible at the CFO’s election upon the consummation of the Company’s Business Combination. Upon such election, the notes will convert, at a price of $10.00 per unit, into units identical to the private placement units issued in connection with the Company’s Initial Public Offering.
Promissory note related party				$ 770,112		400,112
Convertible promissory note related party				$ 240,112		90,112
Working Capital Loan [Member]
Related Party Transaction [Line Items]
Conversion price				$ 10.00
Convertible carrying amount of equity component				$ 500,000
C F O [Member]
Related Party Transaction [Line Items]
Convertible promissory notes									$ 390,112
Convertible note issued				$ 760,112		390,112
First Convertible Promissory Note [Member]
Related Party Transaction [Line Items]
Principal amount										$ 10,000
Conversion price										$ 10.00
Over-Allotment Option [Member]
Related Party Transaction [Line Items]
Number of shares issued	892,855
Proposed Offering [Member]
Related Party Transaction [Line Items]
Number of shares issued				892,855
Common stock threshold percentage on conversion of shares		20.00%
Founder Shares [Member]
Related Party Transaction [Line Items]
Number of shares issued			2,156,250
Number of shares issued, value			$ 25,000
Founder Shares [Member] \| Over-Allotment Option [Member]
Related Party Transaction [Line Items]
Forfeited, shares					20,536
Sponsor [Member]
Related Party Transaction [Line Items]
Number of shares issued					2,156,250
Number of shares issued, value					$ 25,000
Common stock, shares, outstanding	1,848,214
Sponsor [Member] \| C F O [Member]
Related Party Transaction [Line Items]
Convertible note issued				$ 10,000		$ 10,000
Sponsor [Member] \| Founder Shares [Member]
Related Party Transaction [Line Items]
Number of shares issued		287,500
Temporary equity, shares outstanding	1,848,214	1,868,750
Forfeited, shares	20,536

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		3 Months Ended
	Aug. 12, 2022	Mar. 31, 2024
Subsidiary, Sale of Stock [Line Items]
Underwriting discount percentage		1.00%
Deferred underwriting commission percentage		3.50%
Unrestricted shares		200,000
Granted shares		200,000
Fair value		$ 2,216,000
Share price		$ 11.08
Deferred liability		$ 1,837,499
Deferred underwriting commission		$ 378,501
Percenatge of gross proceeds of the ordinary shares		1.00%
Proposed Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued		892,855
Payments for underwriting expense		$ 739,286
Deferred underwriting commissions noncurrent		2,587,499
Initial business combination		750,000
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued	892,855
Payments for underwriting expense		$ 739,286
Ordinary shares		73,929

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended	12 Months Ended
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Aug. 12, 2022	Jul. 01, 2022	Oct. 24, 2021	Mar. 31, 2024	Dec. 31, 2021	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized				500,000,000		500,000,000
Common stock, par value				$ 0.0001		$ 0.0001
Ordinary shares of initial shareholders				1,437,500
Common Stock dividends, shares			0.50
Temporary equity, shares outstanding				5,127,282		5,127,282
Common stock, shares, issued				2,295,893		2,295,893
Common stock, shares, outstanding				2,295,893		2,295,893
Temporary equity, shares issued				5,127,282		5,127,282
Share price				$ 10.25
IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price	$ 10.00
Warrants issued				7,766,605
Public Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants issued				7,392,855
Private Placement Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants issued				373,750
Public Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercisable term from the date of completion of business combination				30 days
Warrants not exercisable term from the consummation of business combination				90 days
Ordinary Shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares, issued				2,295,893		2,295,893
Common stock, shares, outstanding				2,295,893		2,295,893
Common Class A [Member] \| Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Redemption trading period				30 days
Common Class A [Member] \| Redemption Of Warrants [Member] \| Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrants, redemption price per unit				0.01
Redemption notice period				30 days
Share price				$ 18
Number of consecutive trading days for determining share price				20 days
Number of trading days for determining share price				30 days
Sponsor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued					2,156,250
Number of shares issued, value					$ 25,000
Common stock, shares, outstanding	1,848,214
Founder Shares [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued			2,156,250
Number of shares issued, value			$ 25,000
Founder Shares [Member] \| Sponsor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued		287,500
Temporary equity, shares outstanding	1,848,214	1,868,750
Forfeited shares	20,536

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Aug. 05, 2024	Aug. 06, 2024	Apr. 01, 2024	Mar. 31, 2024	Dec. 31, 2023
Subsequent Event [Line Items]
Due to related party				$ 62,260	$ 54,535
Unrelated Third Party [Member]
Subsequent Event [Line Items]
Principal amount				$ 300,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Due to related party			$ 144,060
Annual interest rate	9.127%
Notes payable		$ 300,000
Deposits		$ 400,000
Subsequent Event [Member] \| C F O [Member]
Subsequent Event [Line Items]
Payment to related party			81,800
Subsequent Event [Member] \| Promissory Note One Two Three Four And Five For Working Capital And Extension Purposes [Member] \| C F O [Member]
Subsequent Event [Line Items]
Principal amount			$ 81,000
Subsequent Event [Member] \| Second Convertible Promissory Note [Member] \| Zheng Yuan [Member]
Subsequent Event [Line Items]
Conversion Price			$ 10.00
Subsequent Event [Member] \| Unrelated Third Party [Member]
Subsequent Event [Line Items]
Principal amount	$ 300,000